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closure in high risk patients.
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BACKGROUND Percutaneous LAA closure is increasingly performed
in patients with atrial ﬁbrillation and contraindications to anti-
coagulation to lower their stroke and systemic embolism risk. The
safety and efﬁcacy of LAA closure relies on accurate device sizing,
which necessitates accurate measurement of LAA dimensions. LAA
size may change with volume status, and as patients are fasting for
these procedures, intraprocedural measurements may not be repre-
sentative of true LAA size. The objective of this study was to deter-
mine whether volume loading alters the left atrial appendage (LAA)
dimensions in patients undergoing percutaneous LAA closure.
METHODS Thirty-oneconsecutivepatientsundergoingpercutaneousLAA
closure who received volume loading during the procedure were included
in this study. After an overnight fast and induction of general anesthesia,
patients had their LAA dimensions (oriﬁce and depth) measured by trans-
esophageal echocardiography before and after 500-1000ml of intravenous
normal saline, aiming for a left atrial pressure >12mmHg.
RESULTS Successful implantation of LAA closure device was ach-
ieved in all patients. The average oriﬁce size of the LAA at baseline
was 20.5mm at 90 degrees, and 22.5mm at 135 degrees. Following
volume loading, the average oriﬁce size of the LAA increased to
22.5mm at 90 degrees, and 23.5mm at 135 degrees. The average in-
crease in oriﬁce was 1.9mm (p<0.0001). The depth of the LAA also
increased by an average of 2.5mm after volume loading (p<0.0001).
CONCLUSIONS Intraprocedural volume loading with saline increased
the LAA oriﬁce and depth dimensions during LAA closure. Operators
should consider optimizing the left atrial pressure with volume
loading before ﬁnal device sizing.
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BACKGROUND Left atrial (LA) appendage closure using Watchman
device was reported to be effective for atrial ﬁbrillation (AF) patients
to prevent stroke, systemic embolism, and cardiovascular death
compared with warfarin therapy. However, there are some cases with
thrombus formation in LA attached to Watchman device (Figure). In
this study, we investigated incidence, characteristics, and clinical
course of LA thrombus attached to Watchman device.
METHODS From June 2006 to March 2014, consecutive 119 AF patients
underwent the Watchman procedure in our institute. Transesophageal
echocardiographic (TEE) follow-upwas scheduled at 45 days, 6months,
and 12 months after procedure. The incidence of thrombus formation
attached to the device in TEE was evaluated. Furthermore, the patient
characteristics and clinical course were also investigated.
RESULTS Follow-up TEE identiﬁed LA thrombus attached to
Watchman device in 4 patients (3.4%). The prevalence of chronic AF
was signiﬁcantly higher in patients with thrombus than those without
thrombus (100% vs. 40.0%, p ¼ 0.03). Mean CHADS2 score tended to
be higher in patients with thrombus (3.8  0.6 vs. 2.5  0.1, p ¼ 0.06).
The thrombus type and anticoagulation status of each patient were
summarized in Table. Warfarin therapy was restarted or continued
after detection of the thrombus. The thrombus was disappeared in all
patients at subsequent follow-up TEE, and they can discontinue
warfarin therapy within 6 months after the detection of thrombus.The mean follow-up duration was 1456  546 days, and there were no
death, stroke, and systemic embolism events during the follow-up
period.
CONCLUSIONS Thrombus formation attached to Watchman device
can be observed especially in chronic AF patients with higher stroke
risk scores. Even after the detection of thrombus, short-term warfarin
therapy is effective and the clinical outcomes would be favorable.
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BACKGROUND There is limited data with WATCHMAN for left atrial
appendage (LAA) closure in patients with nonvalvular atrial ﬁbrilla-
tion (AF) and contraindications to anticoagulation. The purpose of
this study was to evaluate the safety and efﬁcacy of WATCHMAN in
our early Canadian experience.
METHODS We report our consecutive series of patients who under-
went WATCHMAN implantation at 4 Canadian centers (Vancouver
General Hospital, Montreal Heart Institute, Hamilton General Hospital
and Ottawa Heart Institute). Indications for LAA closure were
CHADS21, and contraindication/intolerance to or failure on anti-
coagulation. All cases were done under general anesthesia and
transesophageal echocardiography (TEE) guidance. Majority of pa-
tients received dual antiplatelet therapy (DAPT) for 3-6 months after
implant. Follow-up TEE was typically performed at 1-6 months post-
procedure.
RESULTS Ninety patients underwent LAA closure with WATCHMAN
from May 2013 to June 2015. The mean age was 75.0  7.9. The mean
CHADS2 score was 2.9  1.2, CHADS-VASc score was 4.4  1.5, and
HASBLED score was 3.2  1.2. Permanent AF was present in 66.7% and
paroxysmal AF in 33.3%. Indications for LAA closure were prior
bleeding in 81 patients (90.0%; 74 major bleeding, and 7 minor
bleeding), 9 were deemed high-risk for bleeding (renal failure,
cirrhosis, labile INR, esophageal ulcers, on DAPT), and 1 with recurrent
strokes on warfarin. Procedural success was 97.8% (88/90), with one
device embolization (snared percutaneously) and one implant failure
due to inadequate LAA depth. There was no procedural stroke/TIA,
death, MI, or cardiac tamponade. There were 3 major bleeding that
required transfusions. Mean hospital stay was 1.4  1.8 days. Antith-
rombotic therapy post-implant included DAPT in 66/90 (73.3%),
anticoagulant in 21/90 (5 warfarin, 16 direct anticoagulant), and
aspirin alone in 3/90. Follow-up TEE was available in 53 patients,
there was 1 device-associated thrombus (treated successfully with
